Spexis AG
SIX:SPEX

Watchlist Manager
Spexis AG Logo
Spexis AG
SIX:SPEX
Watchlist
Price: 0.01 CHF -75% Market Closed
Market Cap: 3.9m CHF

Spexis AG
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Spexis AG
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Spexis AG
SIX:SPEX
EPS (Diluted)
CHf0
CAGR 3-Years
55%
CAGR 5-Years
42%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
EPS (Diluted)
-$5
CAGR 3-Years
15%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
EPS (Diluted)
CHf5
CAGR 3-Years
303%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
EPS (Diluted)
CHf0
CAGR 3-Years
53%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
EPS (Diluted)
CHf0
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Relief Therapeutics Holding SA
SIX:RLF
EPS (Diluted)
-CHf1
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Spexis AG
Glance View

Market Cap
3.9m CHF
Industry
Biotechnology

Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.

SPEX Intrinsic Value
Not Available

See Also

What is Spexis AG's EPS (Diluted)?
EPS (Diluted)
-0.4 CHF

Based on the financial report for Dec 31, 2023, Spexis AG's EPS (Diluted) amounts to -0.4 CHF.

What is Spexis AG's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
42%

Over the last year, the EPS (Diluted) growth was 3%. The average annual EPS (Diluted) growth rates for Spexis AG have been 55% over the past three years , 42% over the past five years .

Back to Top